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Abstract
Introduction: Gliostatin/thymidine phosphorylase (GLS/TP) has angiogenic and arthritogenic activities, and aberrant
GLS production has been observed in the active synovial membranes of rheumatoid arthritis (RA) patients. The
human GLS gene promoter contains at least seven consensus binding sites for the DNA binding protein Sp1. Here
we examined whether Sp1 is necessary for GLS production in RA. We also studied the effects of the Sp1 inhibitor
mithramycin on GLS production in RA fibroblast-like synoviocytes (FLSs).
Methods: FLSs from RA patients were treated with specific inhibitors. The gene and protein expression of GLS
were studied using the quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and an enzyme
immunoassay. Intracellular signalling pathway activation was determined by western blotting analysis, a luciferase
assay, a chromatin immunoprecipitation (ChIP) assay and a small interfering RNA (siRNA) transfection.
Results: The luciferase and ChIP assays showed that Sp1 binding sites in the GLS promoter were essential for GLS
messenger RNA (mRNA) expression. GLS production was suppressed in FLSs by siRNA against Sp1 transfection.
Mithramycin decreased GLS promoter activity, mRNA and protein expression in FLSs. Tumour necrosis factor-a
(TNF-a) significantly increased GLS expression in RA FLSs; this effect was reduced by pre-treatment with
cycloheximide and mithramycin.
Conclusions: Pretreatment of mithramycin and Sp1 silencing resulted in a significant suppression of GLS
production in TNF-a-stimulated FLSs compared to controls. GLS gene expression enhanced by TNF-a was partly
mediated through Sp1. As physiological concentrations of mithramycin can regulate GLS production in RA,
mithramycin is a promising candidate for anti-rheumatic therapy.
Introduction
Many components of the immune system contribute to
the development and progression of rheumatoid arthritis
(RA), and angiogenesis is considered a critical step in its
initiation and progression. Levels of inflammatory cyto-
kines such as tumor necrosis factor-alpha (TNF-a) and
interleukin-1-beta (IL-1b) and IL-6 [1-3] are increased
in arthritic joints, whereas high levels of angiogenic fac-
tors such as vascular endothelial growth factor (VEGF)
[4,5] and gliostatin (GLS) [6,7] have been reported in
synovial fluid and sera from patients with RA. For this
reason, the past decade has seen the development of
biological treatments for RA, such as TNF-a inhibitors.
GLS is thought to be similar to thymidine phosphory-
lase (TP) and platelet-derived endothelial cell growth fac-
tor (PD-ECGF) [8] and induces angiogenesis through the
proliferation and chemotactic migration of endothelial
cells [9-11]. It also inhibits the growth of glial cells [12],
promotes glial cell differentiation, and has neurotrophic
effects on cortical neurons [13]. GLS production by cul-
tured RA fibroblast-like synoviocytes (FLSs) was shown
to be enhanced by TNF-a [14], IL-1b [15], and GLS itself
[16]. GLS was also found to induce VEGF expression in
FLSs [14], and we reported that direct injection of GLS
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into rabbit knees led to pronounced RA-like synovitis
[17]. Inhibition of GLS is therefore regarded as an impor-
tant approach in reducing damage to RA tissues.
Analysis of the TP promoter region revealed several
potential zinc finger-type transcription factor Sp1-binding
sites, including those in numerous housekeeping and
inducible genes [18], in the interferon-stimulated response
element (ISRE), and in the gamma-activated sequence
[19]. In the present study, we used a luciferase assay and a
small interfering RNA (siRNA) against Sp1 to show that
the Sp1 box is essential for GLS production. We also used
the inhibitor mithramycin to demonstrate the effect of
Sp1-binding inhibition on GLS expression. Mithramycin is
an aureolic acid anti-neoplastic antibiotic used for treating
cancer-related hypercalcemia, leukemia [20], and testicular
cancer [21] and prevents Sp1 from binding to its cognate
site in DNA by modifying CG sequences [22]. Here, we
show that mithramycin potently suppresses GLS induction
through the transduction of Sp1 in RA FLSs.
Materials and methods
Preparation of human fibroblast-like synoviocytes
This study was approved by the ethics committee of
Nagoya City University (Nagoya City, Japan). Before parti-
cipation, informed consent was obtained from all subjects
in accordance with the Declaration of Helsinki. FLSs were
cultured from the synovial tissues of 10 patients who had
RA, who were undergoing total knee arthroplasty, and
who met the American Rheumatism Association 1987
revised criteria for the classification of RA [23], as pre-
viously described [24-26]. The clinical characteristics of
these patients are shown in Table 1. FLSs were maintained
in Dulbecco’s modified Eagle’s medium supplemented
with penicillin (100 units per mL), streptomycin (100 μg/
mL), and 10% fetal bovine serum at 37°C in a 5% CO2
atmosphere. The cultures were found to be completely
free of lymphoid and monocytic cells. Cells were allowed
to adhere overnight, and then non-adherent cells were
removed and adherent FLSs were split at a 1:3 ratio when
they reached 70% to 80% confluency. FLSs were used
between passages 3 and 9, during which time they were a
homogeneous population of cells.
Luciferase assay
The 1,243-base pair (bp) GLS/TP promoter fragment was
a kind gift from Mayumi Ono (Department of Pharmaceu-
tical Oncology, Kyushu University, Fukuoka, Japan) [19].
The fragment was cloned into luciferase gene Basic Vector
2 (NIPPON GENE CO., LTD, Tokyo, Japan) and digested
with XhoI and HindIII. This reporter construct was desig-
nated pTP-Luc1. To prepare other deletion constructs,
pTP-Luc1 was digested with different restriction enzymes,
including XhoI, StuI, SacI, and KpnI. Both 5’ overhangs
and 3’ overhangs of the digested product were blunted by
T4 DNA polymerase (Takara Bio Inc., Otsu, Japan) and
self-ligated by T4 DNA ligase (Takara Bio Inc.) to produce
pGLS/TP I, pGLS/TP II, and pGLS/TP III (Figure 1).
FLSs were seeded into a 48-well culture plate (5 × 103
cells per well) and incubated at 37°C in a humidified atmo-
sphere of 5% CO2/air for 1 week. They were then co-
transfected with luciferase reporter vector (400 ng/well)
and pRL-SV40 internal control construct (10 ng/well)
(Promega Corporation, Madison, WI, USA) by using Lipo-
fectamine™ LTX (0.5 μL/well) and Plus™ Reagent
(0.5 μL/well) (Invitrogen Corporation, Life Technologies
Corporation, Carlsbad, CA, USA). The medium was
replaced after 12 hours, and FLSs were treated with 100 or
300 nM mithramycin (Sigma-Aldrich, St. Louis, MO,
USA) for 24 hours. Cells were harvested by using passive
lysis buffer (65 μL/well), and the luciferase activity was
measured by using a Dual-Luciferase Assay System (Pro-
mega Corporation) and normalized to the internal control.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation (ChIP) assays were per-
formed by using ChIP-IT™ Express kits (Active Motif,
Carlsbad, CA, USA) in accordance with a reported proto-
col [27] with minor modifications. In brief, 1.0 × 106 FLSs
cells from 60-mm dishes were treated with or without
300 nM mithramycin for 24 hours and then harvested.
Cells were cross-linked by formaldehyde (1% final concen-
tration) and incubated at room temperature for 10 min-
utes. Cells were then washed with ice-cold phosphate-
buffered saline (PBS) containing protease inhibitors, and
the fixation reaction was stopped by adding 10 mL of Gly-
cine Stop-Fix Solution (Active Motif). Samples were lysed
for 30 minutes in lysis buffer on ice, and the chromatin
Table 1 Clinical characteristics of patients
Characteristic n = 10
Gender, female/male 7/3
Age in years, range (mean) 48-74 (65.0)
Disease duration in years, range (mean) 1-18 (10.6)
CRP in mg/dL, range (mean) 0.05-3.34 (0.66)
ESR in mm/hour, range (mean) 1-83 (20.8)
Rheumatoid factor, positive/negative 9/1
Anti-CCP antibody in U/mL, range (mean) 0.6-100 (37.8)
MMP-3 in ng/mL, range (mean) 38.9-525.7 (222)
Steinbrocker stage, I/II/III/IV 0/5/3/2





Patients using oral steroids 5
Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DMARD,
disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate;
MMP-3, matrix metalloproteinase-3.
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was sheared by sonicating 20 times for 40 seconds each at
maximum power with an ultrasonic processor, including
30 seconds of cooling on ice between each pulse (Misonix,
Inc., Farmingdale, NY, USA). Cross-linked and released
chromatin fractions were immunoprecipitated with mag-
netic beads, Sp1 antibodies, and non-specific IgG (rabbit)
on a rolling shaker overnight at 4°C. Cross-linking of the
immunoprecipitates containing fragmented DNA was che-
mically reversed, and the polymerase chain reaction (PCR)
was performed with MESA GREEN qPCR MasterMix Plus
for SYBR Assay I Low ROX (Eurogentec, San Diego, CA,
USA). The PCR primers used for amplifying promoters
containing the Sp1-binding site furthest upstream were 5’-
AACTGTGGGCCTTCCCACTC-3’ and 5’-TGCTGAGGT
CCTCGAAGAAAC-3’, which produced a 227-bp frag-
ment (Figure 2a).
Western blot analysis for Sp1
FLSs were incubated in 60-mm dishes with 1 ng/mL TNF-
a (R&D Systems, Minneapolis, MN, USA) in the presence
or absence of mithramycin. To prepare nuclear extracts,
cells were rinsed in ice-cold PBS and lysed in 10 mM Tris-
HCl (pH 7.5), 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.5% Nonidet P-40, and a protease inhibitor
cocktail (Sigma-Aldrich) for 10 minutes at 4°C. Cell lysates
were centrifuged at 20,000 g for 10 minutes at 4°C to sepa-
rate the cytoplasmic fraction (supernatant). Insoluble
materials were dissolved in sodium dodecyl sulphate sam-
ple buffer to collect the nuclear extracts. After measuring
Figure 1 Effects of mithramycin on gliostatin/thymidine phosphorylase (GLS/TP) promoter activity based on deletion constructs.
Closed ovals indicate Sp1-binding sites. Open ovals indicate interferon-stimulated response element (ISRE) and gamma-activated sequence (GAS)
sequences. Fibroblast-like synoviocytes were transiently transfected with deletion constructs and then incubated with mithramycin (100 nM,
shaded column, or 300 nM, closed column) for 24 hours. Control cells were incubated without mithramycin (open column). Data were
normalized by measuring the luminescent reaction of the internal control. Results are presented as mean ± standard error of the mean of five
determinations. Statistical significance was calculated by using the Mann-Whitney U test: compared with samples without mithramycin *P < 0.05,
**P < 0.01; compared with samples with pTP-Luc1 without mithramycin †P < 0.01.
Figure 2 Effect of mithramycin on Sp1 binding with chromatin
immunoprecipitation (ChIP) assays. Closed ovals indicate Sp1-
binding sites. Open ovals indicate interferon-stimulated response
element (ISRE) and gamma-activated sequence (GAS) sequences.
Arrows indicate the polymerase chain reaction primers used for
amplifying gliostatin/thymidine phosphorylase (GLS/TP) promoter
containing the Sp1-binding site furthest upstream (A). Confluent
fibroblast-like synoviocytes were incubated in the presence or
absence of 300 nM mithramycin for 24 hours. Sp1 binding to the
furthest upstream Sp1-binding site within the GLS/TP promoter was
detected by ChIP assays. This binding was suppressed by treatment
with mithramycin (B). Similar observations were obtained at least
three times. bp, base pairs; MIT, mithramycin.
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the protein concentration, samples (20 μg of total protein/
lane) were loaded and separated by electrophoresis on a
7.5% polyacrylamide gel (Bio-Rad Laboratories, Hercules,
CA, USA) and then transferred to a polyvinylidene difluor-
ide membrane (Immobilin-P; EMD Millipore, Billerica,
MA, USA). The blots were blocked for 60 minutes with
5% non-fat dry milk in Tris-buffered saline containing
0.1% Tween 20 (TBS-T) and then incubated with an anti-
Sp1 antibody (1:1,000; Cell Signaling Technology, Inc.,
Danvers, MA, USA), anti-lamin C (1:1,000; ImmuQuest
Ltd, Seamer, North Yorkshire, UK), and anti-a-tubulin
antibody (1:1,000; Cell Signaling Technology, Inc.) as load-
ing controls in TBS-T for 2 hours at room temperature.
After three washes with TBS-T, membranes were incu-
bated with appropriate horseradish peroxidase-conjugated
secondary antibodies in TBS-T (1:3,000; GE Healthcare,
Little Chalfont, Buckinghamshire, UK) for 1 hour at room
temperature and washed three times with TBS-T. Protein
bands were detected by using the ECL Plus Western
Blotting Detection System (GE Healthcare) and then
quantified with a densitometric scanner by using ImageJ
software [28].
Reverse transcription-polymerase chain reaction assay
Expression of the GLS gene was assessed by using reverse
transcription-PCR (RT-PCR). Total RNA was isolated by
using TRIzol reagent (Invitrogen Corporation), and RT
was carried out by using random primers and Ready-To-
Go You-Prime First-Strand Beads (GE Healthcare). The
resultant cDNA was subjected to real-time PCR by using a
7500 Fast Real-time PCR System (Life Technologies Cor-
poration) with MESA GREEN qPCR MasterMix Plus for
SYBR Assay I Low ROX (Eurogentec) and primers. The
PCR conditions were an initial denaturation at 95°C for
10 minutes, followed by 40 cycles at 95°C for 5 seconds
and 60°C for 1 minute. The relative quantification value of
GLS was normalized to an endogenous control, b-actin,
after confirming that the GLS and b-actin cDNAs were
amplified with the same efficiency. The primers were as
follows: GLS, 5’-ACAGGAGGCACCTTGGATAA-3’ and
5’-CCGAACTTAACGTCCACCAC-3’ (272 bp), and b-
actin, 5’-GACCTGACTGACTACCTCAT-3’ and 5’-
TCGTCATACTCCTGCTTGCT-3’ (542 bp).
RNA interference
Sp1 Stealth siRNAs and negative control siRNA were pur-
chased from Invitrogen Corporation. The following Sp1
siRNA oligos were used: sense sequence 5’-GACAGGU-
CAGUUGGCAGACUCUACA-3’ and anti-sense sequence
5’-UGUAGAGUCUGCCAACUGACCUGUC-3’. FLSs
were transfected with the indicated combinations of
siRNA against Sp1 or negative control siRNA at a final
concentration of 20 nM by using Lipofectamine
RNAiMAX transfection reagent (Invitrogen Corporation)
in accordance with the recommendations of the manufac-
turer. FLSs were harvested for Western blotting 48 hours
after transfection. FLSs were incubated for 24 hours after
transfection and further incubated with 1 ng/mL TNF-a
for 24 hours and harvested for RT-PCR.
Enzyme immunoassay for gliostatin
GLS was measured by using an enzyme immunoassay
system, as described by Hirano and colleagues [29].
Polyclonal antibodies on the solid phase were obtained
by immunizing New Zealand albino rabbits with 40 μg
of purified natural human GLS, and the monoclonal
antibody was used with the b-galactosidase-labeled sec-
ondary antibody. The detection limit of this assay was
150 pg/mL, and no significant cross-reactivity or inter-
ference was observed. The GLS concentration in cul-
tured FLSs was normalized to the protein content, as
measured by using a Pierce BCA protein assay kit
(Thermo Fisher Scientific, Waltham, MA, USA).
Immunocytochemistry
Confluent FLSs in chambered slides coated with BD
Matrigel Matrix (BD Biosciences, Franklin Lakes, NJ,
USA) were fixed for 30 minutes in 3% paraformaldehyde,
permeabilized with 0.2% Triton X-100 for 5 minutes,
washed with PBS, and blocked for 60 minutes at room
temperature with blocking solution comprising 3% bovine
serum albumin and 0.1% glycine in PBS. After washing,
cells were labeled overnight at 4°C with the primary anti-
body (1:1,000 anti-TP/GLS antibody; a gift from Chugai
Pharmaceutical Co., Ltd., Tokyo, Japan). Cells were
washed and labeled with an Alexa Flour 594-labeled (red)
goat anti-mouse IgG (1:1,000; Molecular Probes Inc., now
part of Invitrogen Corporation) secondary antibody. After
washing, sections were mounted on glass slides containing
ProLong Gold Antifade with 4’,6-diamidino-2-phenylin-
dole (DAPI) (Invitrogen Corporation). Stained cells were
visualized by using an AX70 fluorescence microscope
(Olympus, Tokyo, Japan). Total red intensity of immunos-
taining in nine random fields was quantified by ImageJ.
The numbers of cells were counted in the fields. Data
were presented as mean of intensity per cell.
Statistical analysis
All data were entered into an electronic database and ana-
lyzed by using GraphPad Prism 4 (GraphPad Software,
Inc., San Diego, CA, USA). Data are expressed as the
mean ± standard error of the mean unless otherwise sta-
ted. The statistical significance of the differences was
examined by using the Mann-Whitney U test. In all cases,
P values of less than 0.05 were considered to be statisti-
cally significant.
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Results
Mithramycin inhibited gliostatin gene expression
We prepared three deletion constructs of the GLS/TP
promoter and fused them to the reporter luciferase plas-
mid (Figure 1) to investigate whether mithramycin
inhibited GLS/TP promoter activity. The promoter
activity was expressed relative to the internal control.
Treatment with mithramycin inhibited the promoter
activity in RA FLSs transfected with pTP-Luc1 (55.5%,
100 nM mithramycin; 59.2%, 300 nM mithramycin),
whereas promoter activity was measured at 41.8% in RA
FLSs transfected with pGLS/TP I, relative to those
transfected with pTP-Luc1. The observed inhibition was
accelerated following treatment with mithramycin
(38.2%, 100 nM mithramycin; 35.1%, 300 nM mithramy-
cin) in RA FLSs transfected with pGLS/TP I. The pro-
moter activity of pGLS/TP II and pGLS/TP III was
largely inhibited with or without mithramycin.
Analysis of the gliostatin/thymidine phosphorylase
promoter by using a chromatin immunoprecipitation
assay
We performed a ChIP assay to confirm Sp1 binding to
the promoter and examined the inhibitory effect of
mithramycin on GLS gene expression. Sp1 was shown
to bind to the furthest upstream Sp1-binding site of the
GLS/TP promoter fragment (1,243 bp). Treatment with
mithramycin suppressed binding at this site (Figure 2b).
No amplification band was observed by using the non-
specific rabbit IgG, indicating the specificity of the DNA
immunoprecipitation and ChIP assays.
Nuclear accumulation of Sp1 in response to TNF-a and
mithramycin
To examine whether the nuclear localization of Sp1
changed following treatment with TNF-a or mithramy-
cin, we prepared nuclear extracts from FLSs treated with
or without 300 nM mithramycin for 30 minutes, further
incubated with 1 ng/mL TNF-a for 24 hours, and then
subjected to immunoblotting with anti-Sp1, anti-lamin C,
and anti-a-tubulin antibodies. TNF-a treatment led to a
remarkable accumulation of Sp1 in nuclear extracts,
which was inhibited by treatment with mithramycin (Fig-
ure 3). The nuclear extracts were stained by the anti-
lamin C antibody as a nuclear lamin marker but not by
the anti-a-tubulin antibody as a cytoplasmic marker.
Inhibition of gliostatin expression by RNA interference
To investigate the direct effect of Sp1 on GLS expression,
we employed an siRNA against Sp1 for as an approach to
inhibit GLS expression. The efficiency and specificity of
siRNA gene knockdown of Sp1 were determined by Wes-
tern blotting for Sp1 expression. Sp1 siRNA suppressed
the Sp1 protein expression (Figure 4a). Sp1 siRNA
Figure 3 Effect of tumor necrosis factor-alpha (TNF-a) and
mithramycin on Sp1 protein expression in fibroblast-like
synoviocyte nuclei. Fibroblast-like synoviocytes were cultured to
confluence in the presence or absence of 300 nM mithramycin for
30 minutes and then further incubated with or without TNF-a (1
ng/mL) for 24 hours. Nuclear extracts were processed for
immunoblotting with an anti-Sp1 antibody. Anti-lamin C and anti-a-
tubulin immunoblotting were included to assess the purities of
nuclear and cytoplasmic fractions, respectively. Results are presented
as mean ± standard error of the mean of five determinations.
Statistical significance compared with controls was calculated by
using the Mann-Whitney U test: compared with controls *P < 0.05;
compared with samples with TNF-a alone †P < 0.01. MIT,
mithramycin.
Figure 4 Effect of Sp1 RNA interference on gliostatin (GLS)
expression. Western blotting analysis shows that Sp1 small
interfering RNA (siRNA) (20 nM) transfection for 48 hours strikingly
blocked Sp1 expression compared with negative control (NC) siRNA
(20 nM) transfection (A). After Sp1 or NC siRNA transfection for 24
hours, cells were treated with tumor necrosis factor-alpha (TNF-a) (1
ng/mL) for 24 hours. GLS mRNA expression levels are presented as
mean ± standard error of the mean of five determinations (B). GLS
mRNA levels are represented relative to b-actin. Statistical
significance was calculated by using the Mann-Whitney U test:
compared with NC siRNA samples *P < 0.01; compared with NC
siRNA samples with TNF-a †P < 0.01.
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reduced TNF-a-induced GLS gene expression by 56.7%
at 48 hours post-transfection (Figure 4b).
Effects of mithramycin on gliostatin production
stimulated by TNF-a in cultured fibroblast-like
synoviocytes
FLSs were treated in the presence or absence of 10 to
300 nM mithramycin for 30 minutes and then further
incubated with 1 ng/mL TNF-a for 24 hours. GLS mRNA
(Figure 5a) and protein (Figure 5b) levels were significantly
induced by treatment with TNF-a alone (11.3-fold and
2.1-fold compared with the control, respectively), and
these inductions were suppressed by mithramycin treat-
ment in a dose-dependent manner. GLS was not induced
by treatment with mithramycin alone. We confirmed the
non-toxic concentration at least 48 hours after incubation
with 10 to 300 nM mithramycin and 1 ng/mL TNF-a by
using WST-8 assays (Cell Counting Kit-8; Dojindo
Laboratories, Kumamoto, Japan) (data not shown). GLS
mRNA expression increased in response to TNF-a (1 ng/
mL) and reached a maximum at 24 hours (21.9-fold com-
pared with the level at 0 hours) (Figure 5c). GLS protein
expression increased in response to TNF-a and continued
to rise until at least 48 hours after treatment (5.6-fold
Figure 5 Mithramycin suppression of tumor necrosis factor-alpha (TNF-a)-induced gliostatin (GLS) expression in fibroblast-like
synoviocytes (FLSs). Confluent FLSs were incubated in the presence or absence of 10 to 300 nM mithramycin for 30 minutes and then with
TNF-a for 24 hours. GLS gene expression levels are represented relative to b-actin (A). Immunoreactive GLS was determined by enzyme
immunoassay (B). Results are presented as mean ± standard error of the mean (SEM) of four determinations. Confluent cells were incubated in
the presence (closed circle) or absence (closed square) of 300 nM mithramycin for 30 minutes and then with TNF-a as indicated. Control FLSs
were cultured without TNF-a (closed triangle). GLS mRNA (C) and protein (D) expression levels are presented as mean ± SEM of four
determinations. Statistical significance was calculated by using the Mann-Whitney U test: compared with controls *P < 0.05, **P < 0.01;
compared with samples with TNF-a alone †P < 0.05, ††P < 0.01. MIT, mithramycin.
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compared with the level at 0 hours) (Figure 5d). These
increases in GLS mRNA and protein were significantly
suppressed by 300 nM mithramycin treatment. To con-
firm whether TNF-a directly regulates GLS expression,
FLSs were pre-treated with the protein synthesis inhibitor,
cycloheximide. TNF-a-induced GLS mRNA production
significantly decreased in a dose-dependent manner with
treatment of cycloheximide (Additional file 1).
FLSs were cultured to confluence in the presence or
absence of 300 nM mithramycin for 30 minutes, followed
by further incubation with or without 1 ng/mL TNF-a for
24 hours. We observed no morphological change in FLSs
during immunocytochemical staining. FLSs were immu-
nostained with GLS antibody (red). Staining was weakly
diffuse in the cytoplasm of FLSs that had not undergone
treatment (Figure 6a). Treatment with mithramycin alone
had no effect on GLS staining. The expression of GLS pro-
tein was significantly induced by treatment with TNF-a
alone (1.5-fold compared with the control). This induction
was significantly suppressed by mithramycin treatment
(0.6-fold compared with the sample induced by TNF-a
alone) (Figure 6b).
Discussion
TNF-a has been identified as a crucial cytokine in the
pathogenesis of RA [30,31] and is involved in the activa-
tion of the nuclear factor-kappa-B (NF-B) transcription
factor [32,33]. In the present study, no NF-B-binding
sites were identified within the upstream GLS/TP promo-
ter examined. It is therefore unlikely that TNF-a directly
modulates transcriptional GLS regulation through bind-
ing the GLS/TP promoter. To determine the principal
elements in the GLS/TP promoter which are relevant to
GLS expression, we constructed a series of deletion
mutant plasmids. Treatment with mithramycin inhibited
GLS/TP promoter activity, confirming the potential for
GLS production through Sp1 binding in FLSs.
Goto and colleagues [19] reported that interferon-
gamma (IFN-g) induced the expression of TP through
ISRE and gamma-activated sequence in human macro-
phages. In the present study, the promoter activity was not
regulated by IFN-g in FLSs (data not shown); however,
this discrepancy could be explained by differences in the
cellular properties of macrophages and FLSs. In addition,
luciferase and ChIP assays showed that the Sp1-binding
Figure 6 Immunocytochemical detection of gliostatin (GLS) in fibroblast-like synoviocytes. Fibroblast-like synoviocytes were stimulated by
the presence or absence of 300 nM mithramycin for 30 minutes, followed by further incubation with or without tumor necrosis factor-alpha
(TNF-a) (1 ng/mL) for 24 hours, and were immunostained with GLS antibody (red). Cell nuclei were stained by 4’,6-diamidino-2-phenylindole
(DAPI) (blue). Scale bar represents 50 μm (A). Total red intensity of immunostaining in a random field was quantified by ImageJ. The numbers of
cells were counted in the field. Data (intensity/cell) were presented as mean ± standard error of the mean (SEM) of nine determinations.
Statistical significance was calculated by using the Mann-Whitney U test: compared with controls *P < 0.05, compared with samples with TNF-a
alone †P < 0.05 (B). MIT, mithramycin.
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sites played an important role in regulating the promoter
activity of the GLS gene and mithramycin exactly behaved
as an Sp1 inhibitor. Other reports suggested that activated
Sp1 is transported into the nucleus [34,35]; this was sup-
ported by our analysis of FLS nuclear fractions by using
Western blotting, which revealed a remarkable accumula-
tion of Sp1 in the nuclei following TNF-a treatment that
was inhibited by treatment with mithramycin. We further
investigated whether Sp1 directly regulated expression of
GLS. We used RNA interference to detect the effects of
Sp1 depletion on GLS expression at the mRNA levels.
We confirmed that TNF-a-induced GLS mRNA and
protein production were inhibited by mithramycin in a
dose-dependent manner. Our immunocytochemical stu-
dies revealed that GLS was stained weakly and diffusely
in FLS cytoplasm that had not undergone treatment. The
intensity of GLS staining was increased by TNF-a treat-
ment and suppressed by mithramycin at concentrations
of 100 to 300 nM. These concentrations did not affect
cell viability, as measured by a WST-8 assay, and an in
vivo study demonstrated that leukemia patients receiving
a 2-hour continuous infusion of 25 μg/kg mithramycin
did not exceed plasma levels of 300 to 350 nM [36].
The protein synthesis inhibitor cycloheximide signifi-
cantly decreased TNF-a-induced GLS mRNA production
in a dose-dependent manner. GLS gene transcription
might require de novo protein synthesis in FLSs stimulated
by TNF-a, although the key protein involved remains to
be identified.
In the pathogenesis of RA, we reported that GLS
increased the expression of VEGF mRNA and protein in
FLSs [14]. As angiogenesis is necessary for the perpetua-
tion of inflammation, inhibition of angiogenic factors such
as GLS and VEGF could provide a means to suppress the
inflammatory cascade in RA synovitis [37]. We also
reported that GLS induced the expression of matrix metal-
loproteinase (MMP)-1 and MMP-3 and GLS itself in FLSs
[16]. The MMP family of proteins, including MMP-1,
MMP-3, and MMP-13, plays a crucial role in excessive
cartilage degradation in RA [38,39]. Other reports indi-
cated that the gene expression levels of VEGF in fibro-
blasts [40,41] and of MMPs in articular chondrocytes [42]
were closely related to that of Sp1. It was suggested, based
on these findings, that an Sp1 inhibitor could be effective
in reducing RA disease activity.
Conclusions
The present study indicates that expression of the GLS
gene is mediated, in part, through the transcription fac-
tor Sp1. Our data suggest that the beneficial effects of
mithramycin in RA might be at least partly due to anti-
angiogenic and anti-arthritogenic activity involving the
downregulation of GLS. Mithramycin is therefore a pro-
mising candidate anti-rheumatic drug.
Additional material
Additional file 1: Effect of cycloheximide on TNF-a induced GLS
mRNA production in FLSs. Confluent FLSs in 6-well plate were
incubated in the presence or absence of 10-100 (μg/ml cycloheximide
for 30 min, followed by further incubation with TNF-a (1 ng/ml) for 24 h.
The GLS mRNA levels are expressed as a RT-PCR product ratio (GLS/b-
actin). Results are presented as mean ± SEM of four determinations.
Statistical significance compared with controls was calculated using the
Mann-Whitney U-test: compared to controls * P < 0.01; compared to
samples with TNF-a alone † P < 0.01.
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